A
Andrey Loboda
Researcher at Merck & Co.
Publications - 124
Citations - 12418
Andrey Loboda is an academic researcher from Merck & Co.. The author has contributed to research in topics: Cancer & Pembrolizumab. The author has an hindex of 38, co-authored 108 publications receiving 9023 citations. Previous affiliations of Andrey Loboda include Wistar Institute & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers,Jared Lunceford,Michael Nebozhyn,Erin Murphy,Andrey Loboda,David Ross Kaufman,Andrew Albright,Jonathan D. Cheng,S. Peter Kang,Veena Shankaran,Sarina Anne Piha-Paul,Jennifer H. Yearley,Tanguy Y. Seiwert,Antoni Ribas,Terrill K. McClanahan +14 more
TL;DR: The T cell–inflamed GEP contained IFN-&ggr;–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit.
Journal ArticleDOI
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Razvan Cristescu,Robin Mogg,Mark Ayers,Andrew Albright,Erin Murphy,Jennifer H. Yearley,Xinwei Sher,Xiaoqiao Liu,Hongchao Lu,Michael Nebozhyn,Chunsheng Zhang,Jared Lunceford,Andrew K. Joe,Jonathan D. Cheng,Andrea L. Webber,Nageatte Ibrahim,Elizabeth R. Plimack,Patrick A. Ott,Tanguy Y. Seiwert,Antoni Ribas,Terrill K. McClanahan,Joanne E. Tomassini,Andrey Loboda,David Ross Kaufman +23 more
TL;DR: The potential for TMB and a T cell–inflamed GEP to jointly predict clinical response to pembrolizumab was assessed in >300 patient samples with advanced solid tumors and melanoma across 22 tumor types from four KEYNOTE clinical trials.
Journal ArticleDOI
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu,Jeeyun Lee,Michael Nebozhyn,Kyoung-Mee Kim,Jason C. Ting,Swee Seong Wong,Jiangang Liu,Yong Gang Yue,Jian Wang,Kun Yu,Xiang S. Ye,In-Gu Do,Shawn Liu,Lara Gong,Jake Fu,Jason Gang Jin,Min Gew Choi,Tae Sung Sohn,Joon-Ho Lee,Jae Moon Bae,Seung Tae Kim,Se Hoon Park,Insuk Sohn,Sin-Ho Jung,Patrick Tan,Ronghua Chen,James S. Hardwick,Won Ki Kang,Mark Ayers,Dai Hongyue,Christoph Reinhard,Andrey Loboda,Sung Kim,Amit Aggarwal +33 more
TL;DR: This work uses gene expression data to describe four molecular subtypes linked to distinct patterns of molecular alterations, disease progression and prognosis in gastric cancer, and describes key molecular alterations in each of the four subtypes using targeted sequencing and genome-wide copy number microarrays.
Journal ArticleDOI
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim,Razvan Cristescu,Adam J. Bass,Kyoung-Mee Kim,Justin I. Odegaard,Kyung Kim,Xiaoqiao Liu,Xinwei Sher,Hun Jung,Mijin Lee,Su Jin Lee,Se Hoon Park,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Hyuk Lee,Min-Gew Choi,Amir Ali Talasaz,Peter Soonmo Kang,Jonathan D. Cheng,Andrey Loboda,Jeeyun Lee,Won Ki Kang +22 more
TL;DR: Findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.
Journal ArticleDOI
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Zhengyan Kan,Hancheng Zheng,Xiao Liu,Shuyu Li,Thomas D. Barber,Zhuolin Gong,Huan Gao,Ke Hao,Melinda D. Willard,Jiangchun Xu,Robert Hauptschein,Paul A. Rejto,Julio Fernandez,Guan Wang,Qinghui Zhang,Bo Wang,Ronghua Chen,Jian Wang,Nikki P. Lee,Wei Zhou,Zhao Lin,Zhiyu Peng,Kang Yi,Shengpei Chen,Lin Li,Xiaomei Fan,Jie Yang,Rui Ye,Jia Ju,Kai Wang,Heather Estrella,Shibing Deng,Ping Wei,Ming Qiu,Isabella H. Wulur,Jiangang Liu,Mariam Ehsani,Chunsheng Zhang,Andrey Loboda,Wing-Kin Sung,Wing-Kin Sung,Amit Aggarwal,Ronnie T.P. Poon,Sheung Tat Fan,Jun Wang,James S. Hardwick,James S. Hardwick,Christoph Reinhard,Hongyue Dai,Yingrui Li,John M. Luk,John M. Luk,John M. Luk,Mao Mao,Mao Mao +54 more
TL;DR: Findings from a whole-genome sequencing study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, find beta-catenin to be the mostrequently mutated oncogene and TP53 the most frequently mutated tumor suppressor.